


## CANCER INFORMATIVE BIOMARKER SIGNATURE

### DESCRIPTION

- The efficacy of Immune check-point inhibitor (ICI) treatment ranges from **30-40% in sensitive tumors** to **<5% in immune-resistant tumors**.
- **Current Predictive methods have low sensitivity and poor specificity** identifying patients that could benefit from ICI Treatment.
- Cancer informative biomarker signature is an **immune-metabolic signature** that **classifies patients** suffering from different solid tumors **in 3 clusters** depending on their immune-metabolic profile.
- **IMMETCOLS** signature (10-gene signature) improves the **identification of patients with solid tumors** who could benefit from **the combination with ICI and drugs that tackle immune-microenvironment and cancer-metabolism**

### POTENTIAL INDICATIONS


- Immune-metabolic classification
- Predictive Biomarker
- Solid Tumors
- Prognosis and monitoring
- Drug screening tool



## COMPETITIVE ADVANTAGE

- The immune-metabolic signature constitutes a great advance for the selection of the best treatment strategy for each patient suffering from a solid tumor
- **IMMETCOLS** use a **trained NEURAL network based on a 10-gene** signature that can be used **to increase ICI efficacy in combination with selected drugs**
- Easily implemented into decision making for the **management of the most appropriate therapeutic approach**

### STAGE OF DEVELOPMENT



## TEAM

*HCB, IDIBAPS, CSIC, UB and ICREA*

- Dr. Joan Maurel Santasusana
- Dra. Marta Cascante Serratosa
- Dra. Leire Pedrosa Eguilaz
- Dr. Carles Foguet Coll
- Dr. Timothy Thompson Okatsu
- Dr. Antonio Postigo
- Dr. Daniel Benítez Rivas
- Dr. Jordi Camps Polo

## FINANCIAL NEEDS

HCB, IDIBAPS CSIC, UB and ICREA are seeking an industrial partner interested in the product development and commercialization throughout a license agreement. Potential partners are BIG industry and small companies focus on metabolism

## MORE INFO

- Patents:  
European Patent Application PCT/EP2022/073151 - August 2022  
Applicants: HCB, IDIBAPS, CSIC, UB, ICREA